¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"loss mutation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® mutation ÇÑ±Û µ¹¿¬º¯ÀÌ
¼³¸í   
  ¼¼Æ÷ÀÇ dna ÀÚüÀÇ º¯ÀÌ¿¡ ÀÇÇØ ÀϾ´Â ¼¼Æ÷º¯À̸¦ ¸»ÇÑ´Ù. ÀÌ·¯ÇÑ °æ¿ì µ¹¿¬º¯À̷ΠÀϾ ¼¼Æ÷´Â ±× ÀÌÈÄ µþ¼¼Æ÷(daughter cell)¿¡¼­µµ ±× º¯À̰¡ ¿©ÀüÈ÷ À¯ÁöµÇ¹Ç·Î Á¾(species)ÀÇ º¯È­³ª, È¤Àº ¼¼Æ÷ÀÇ ¾Ç¼ºº¯È¯(malignant transformation)¿¡ °ü¿©ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • loss-of-function mutation
    ±â´É¼Ò½Çµ¹¿¬º¯ÀÌ
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®, Çã¿ëÇ÷¾×»ó½Ç·®
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • conductive hearing loss
    ÀüÀ½³­Ã», Àüµµ³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • functional hearing loss
    ±â´É³­Ã»
  • familial progressive hearing loss
    °¡Á·¼ºÁøÇ೭û
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç, û·ÂÀå¾Ö
  • heat loss
    ¿­¼Õ½Ç
  • high velocity signal loss
    °í¼Ó½ÅÈ£¼Ò½Ç
  • ionization loss
    ÀÌ¿ÂÈ­¼Õ½Ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • loss
    »ó½Ç
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • mutation
    µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • reverse mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
  • somatic mutation
    ü¼¼Æ÷µ¹¿¬º¯ÀÌ
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • loss of short-term variability
    ´Ü±âº¯µ¿¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • loss mutation
    »ó½Çµ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • condensed milk conductive hearing loss
    ³óÃà¿ìÀ¯ÀüµµÃ»°¢¼Ò½Ç
  • conductive hearing loss
    Àüµµ³­Ã»
  • conductive hearing loss
    ÀüÀ½¼º³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
  • familial progressive hearing loss
    °¡Á·ÁøÇ೭û
  • functional hearing loss
    ±â´É³­Ã»
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç
  • heat loss
    ¿­¼Õ½Ç
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • frameshift mutation
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ, ÇÁ·¹ÀÓ½¬ÇÁÆ® µ¹¿¬º¯ÀÌ
  • genetic mutation
    À¯ÀüÀû µ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ß¼º µ¹¿¬º¯ÀÌ.
  • plaque morphology mutation
    ÇöóÅ© ÇüÅ µ¹¿¬º¯ÀÌ
  • plaque-type mutation
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡ µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • population mutation
    Áý´Ü±ºµ¹¿¬º¯ÀÌ(¡­ÔÍæÔܨì¶).
  • recessive mutation
    ¿­¼ºµ¹¿¬º¯ÀÌ(æëàõÔÍæÔܨì¶).
  • recessive mutation
    ¿­¼ºµ¹¿¬º¯ÀÌ
  • Heat loss
    ¿­¼Õ½Ç(æðáßã÷)
  • NIHL [=noise induced hearing loss]
    ¼ÒÀ½¼º ³­Ã»
  • abrasion loss
    ¸¶¸ê·®(¸¶¸ê¾ç).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • loss mutation
    »ó½Çµ¹¿¬º¯ÀÌ(ßÃã÷ÔÍæÔܨì¶).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • back mutation
    ¿ªº¯ÀÌ
  • chromosomal mutation
    ¿°»öü(µ¹¿¬)º¯ÀÌ.
  • cold-sensitive mutation
    ÇÑ·©°¨¼ö¼º µ¹¿¬º¯ÀÌ
  • complementation of virus mutation
    ¹ÙÀÌ·¯½ºº¯ÀÌ (Áõ½Ä)º¸¿Ï(¡­ñòãÖÜÍèÇ).
  • conditional lethal mutation
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌ
  • conditional mutation
    Á¶°Çµ¹¿¬º¯ÀÌ
  • dominant mutation
    ¿ì¼º[µ¹¿¬]º¯ÀÌ
  • dominant mutation
    ¿ì¼º(µ¹¿¬)º¯ÀÌ(¡­ÔÍæ×ܨì¶).
  • drift mutation
    ¿¬¼Óº¯ÀÌ(ææáÙܨì¶).
  • frameshift mutation
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ, ÇÁ·¹ÀÓ½¬ÇÁÆ® µ¹¿¬º¯ÀÌ
  • frequency, mutation
    µ¹¿¬º¯À̺óµµ
  • gene mutation
    ÇØºÎ
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ(ÔÍæÔܨì¶).
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ
    [¿¾ ¿ë¾î] À¯ÀüÀÚµ¹¿¬º¯ÀÌ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • coincidence loss
    µ¿½Ã¼Õ½Ç(ÔÒãÁáßã÷)
  • counting loss
    "°èÃø ¼Õ½Ç(ͪö´áßã÷), (ÔÒ) coincidence loss"
  • anucleolate mutation
    ¹«ÇÙÀÎ º¯ÀÌ(Ùíú·ìÝܨì¶)
  • back mutation
    º¹±Íº¯ÀÌ(ÜÖÏýܨì¶)
  • chain termination mutation
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ) º¯ÀÌ(ܨì¶)
  • constitutive mutation
    ±¸¼ºº¯ÀÌ(ϰà÷ܨì¶)
  • copy-error mutation
    º¹»ç¿À·ù º¯ÀÌ(ÜÜÞÐè¦×½Ü¨ì¶)
  • down promoter mutation
    ÇÏÇâÃËÁøÀÚ º¯ÀÌ(ù»ú¾õµòäí­Ü¨ì¶) (ÔÒ) promoter down mutation
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
  • forward mutation
    ³ªÅ¸³² º¯ÀÌ(ܨì¶)
  • frameshift mutation
    ƲÀ̵¿(ì¹ÔÑ) º¯ÀÌ(ܨì¶)
  • germinal mutation
    ¹è¼¼Æ÷ º¯ÀÌ(ÛÏá¬øàܨì¶)
  • induced mutation
    À¯µµº¯ÀÌ(ë¯Óôܨì¶)
  • intergenic suppressor mutation
    À¯ÀüÀÚ°£ ¾ï¾ÐÀÚº¯ÀÌ(ë¶îîí­Êàåääâí­Ü¨ì¶)
  • intragenic suppression mutation
    À¯ÀüÀÚ³» ¾ï¾Ðº¯ÀÌ(ë¶îîí­Ò®åääâܨì¶)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mutation
    µ¹¿¬ º¯ÀÌ
  • central hearing loss
    ÁßÃß¼º û·Â»ó½Ç, ÁßÃß¼º ³­Ã»
  • energy loss
    ¿¡³ÊÁö¼Õ½Ç
  • hearing loss
    û°¢¼Õ½Ç
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • sensorineural hearing loss
    °¨°¢½Å°æ¼º³­Ã»
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • weight loss
    üÁß°¨¼Ò, °¨·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IDA   1) Imino-Diacetic Acid
  2) Iron Deficiency Anemia
   &nb...
ARMS adverse reaction monitoring system; amplification refractory mutation system
MF magnetic field; meat free; medium frequency; megafarad; membrane filler; merthiolate-formaldehyde [s...
TFM testicular feminization male; testicular feminization mutation; total fluid movement; transmission e...
LOC Loss Of Consciousness
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ARMS Amplification Refractory Mutation System
MFD Mutation frequency decline
RIP Repeat Induced Point mutation
RSM Restriction Site Mutation
SMART Somatic Mutation And Recombination Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • amber mutation
    ¾Ïº£¸£ µ¹¿¬º¯ÀÌ
  • auxotrophic mutation
    ¿µ¾ç ¿ä±¸ µ¹¿¬º¯ÀÌ
  • biochemical mutation
    »ýÈ­ÇÐÀû µ¹¿¬º¯ÀÌ
  • clear plaque mutation
    Åõ¸í ÇöóÅ© µ¹¿¬º¯ÀÌ
  • cold-sensitive mutation
    ÇÑ·© ¹Î°¨¼º µ¹¿¬º¯ÀÌ
  • conditional mutation
    Á¶°ÇºÎ µ¹¿¬º¯ÀÌ
  • constitutive mutation
    ±¸¼ºÀû µ¹¿¬º¯ÀÌ
  • frameshift mutation
    °ñ°Ý ±¸Á¶ À̵¿ µ¹¿¬º¯ÀÌ
  • homoetic mutation
    È£¸Þ¿À½Ã½º µ¹¿¬º¯ÀÌ
  • missense mutation
    ¹Ì½º¼¾½º µ¹¿¬º¯ÀÌ
  • mutation
    µ¹¿¬º¯ÀÌ
    1. ÇüÅÂ, ¼º°Ý ȤÀº ¾î¶² ´Ù¸¥ Ư¡¿¡ »ý±ä º¯È­. 2. À¯ÀüÇп¡¼­´Â À¯Àü ¹°Áú¿¡ »ý±ä º¸ÅëÀº ÇϳªÀÇ À¯ÀüÀÚ¿¡ »ý±ä À¯ÀüÀÌ µÇ´Â ¿µ±¸ÀûÀÎ º¯È­. ¶ÇÇÑ °³Ã¼¿¡¼­ ³ªÅ¸³ª´Â º¯È­. ¶ÇÇÑ °íÀü À¯ÀüÇп¡¼­´Â º¯Á¾
  • mutation disturbance
    º¯¼º Àå¾Ö
  • mutation rate
    º¯ÀÌÀ², µ¹¿¬º¯ÀÌÀ²
  • ochre mutation
    ¿À¿ìÄ¿ µ¹¿¬º¯ÀÌ
  • reading framework mutation
    ÆÇµ¶ °ñ°Ý ±¸Á¶ À̵¿ µ¹¿¬º¯ÀÌ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
alveolar bone loss The resorption of bone in the supporting structures of the maxilla or mandible as a result of periodontal disease.
(12 Dec 1998)
axon loss polyneuropathy A type of polyneuropathy in which axon degeneration is the sole/predominant feature; many aetiologies, particularly toxic and metabolic; on nerve conduction studies, affects amplitudes of the responses, but does not cause conduction slowing or block.
Synonym: axonal polyneuropathy.
(05 Mar 2000)
blood loss, surgical Loss of blood during surgery.
(12 Dec 1998)
Parallel Electron Energy Loss Spectroscopy <technique> Electron energy loss spectroscopy analyses the inelastically scattered electrons present in the beam after it has been transmitted through the sample. An electron energy loss spectrum typically consists of a monatomic decreasing background on which are superimposed a number of peaks. Each peak is characteristic of the scattering process that has occurred in the sample. The peaks can be used to obtain information about the chemical composition and electronic structure of the sample. Electron energy loss spectra are acquired typically in a magnetic sector spectrometer located under the camera chamber of the transmission electron microscope. Spatial resolution is typically limited by the minimum probe diameter of the microscope. Electron energy loss spectroscopy tends to be complimentary to EDS in that it can be used to analyse very thin samples of low Z materials.
Acronym: PEELS
(05 Aug 1998)
periodontal attachment loss Loss or destruction of periodontal tissue caused by periodontitis or other destructive periodontal diseases or by injury during instrumentation. Attachment refers to the periodontal ligament which attaches to the alveolar bone. It has been hypothesised that treatment of the underlying periodontal disease and the seeding of periodontal ligament cells enable the creating of new attachment.
(12 Dec 1998)
water loss, insensible Loss of water by diffusion through the skin and by evaporation from the respiratory tract. It is so called because we do not know that we are actually losing water at the time that it is leaving the body. (guyton, textbook of medical physiology, 8th ed, p274)
(12 Dec 1998)
weight loss Decrease in existing body weight.
(12 Dec 1998)
conductive hearing loss <otolaryngology> A form of deafness that results from a blockage of the ear canal or dysfunction of the ossicles or eardrum (sound collecting apparatus).
In conductive hearing loss the auditory nerve is normal, but there exists a physical problem with the sound collecting apparatus.
(05 Jan 1998)
hair loss Hair loss may be associated with aging, hormones (androgens) or genetic predisposition. The pattern of baldness in women is different from that of men. In women there is thinning of the hair all over the scalp, but the frontal hairline is maintained. The hair loss is usually permanent. Treatment has been successful with topical minoxidil in some cases.
(13 Nov 1997)
hearing loss, bilateral Partial hearing loss in both ears.
(12 Dec 1998)
hearing loss, central Hearing loss due to central nervous system disease, anywhere in the auditory pathways from the cochlear nucleus of the pons to the auditory cortex.
(12 Dec 1998)
hearing loss, conductive Hearing loss due to interference with the acoustic transmission of sound to the cochlea. The interference is in the outer or middle ear.
(12 Dec 1998)
hearing loss, functional Hearing loss without a physical basis.
(12 Dec 1998)
hearing loss, high-frequency Hearing loss in frequencies above 1000 hertz.
(12 Dec 1998)
hearing loss, noise-induced Hearing loss from exposure to noise. The loss is often in the frequency range 4000-6000 hertz.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • be at a loss
    ºÒÈ®½ÇÇÑ »óÅ¿¡ ÀÖ´Ù
  • loss
    ºÐ½Ç
  • mutation
    º¯°æ
  • consequential loss insurance
    °£Á¢ ¼ÕÇØ º¸Çè
  • dead loss
    Àü¼Õ
  • forward mutation
    ÀüÁø µ¹¿¬ º¯ÀÌ
  • frameshift mutation
    ÇÁ·¹ÀÓ½ÃÇÁÆ® µ¹¿¬ º¯ÀÌ
  • friction loss
    ¸¶Âû¼Õ½Ç
  • loss
    ¼Õ½Ç;»ó½Ç;¼ÕÇØ;½ÇÆÐ;ÆÐ¹è;¼Ò¸ð;at a ~ °ï¶õÇÏ¿©;¾î¿ ÁÙ ¸ô¶ó¼­
  • loss leader
    Ư¸Åǰ
  • missense mutation
    ¹Ì½º¼¾½º µ¹¿¬ º¯ÀÌ
  • mutation
    º¯È­;µ¹¿¬ º¯ÀÌ;º¯Á¾;¸ðÀ½ º¯È­
  • neutral mutation
    Á߸³µ¹¿¬º¯ÀÌ
  • vowel mutation
    =UMLAUT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á